Skip to main content

Table 3 Changes in baseline to endpoint measures for insulin resistance in two groups

From: Randomized double blind clinical trial evaluating the Ellagic acid effects on insulin resistance, oxidative stress and sex hormones levels in women with polycystic ovarian syndrome

Variables Mean ± SD
Placebo(n = 28)
Mean ± SD
Ellagic acid (n = 29)
P1
FBS (mg/dL) Baseline 107.61 ± 20.13 111.17 ± 18.04 0.3
End 106.17 ± 21.09 94.29 ± 17.43 0.043
P2 0.622 0.035  
Mean Changes -1.44 ± 0.96 -16.88 ± 0.61 0.04
Insulin (µU/ml) Baseline 14.98 ± 3.07 15.41 ± 3.24 0.327
End 14.04 ± 2.19 9.63 ± 1.31 0.03
P2 0.541 0.027  
Mean Changes -0.94 ± 0.88 -5.78 ± 1.93 0.041
HOMA-IR Baseline 3.98 ± 0.85 4.22 ± 1.14 0.272
End 3.68 ± 0.41 2.24 ± 0.5 0.04
P2 0.158 0.031  
Mean Changes -0.3 ± 0.44 -1.98 ± 0.64 0.043
  1. Data are expressed as means ± SD. FBS Fasting Blood Sugar, HOMA-IR Homeostatic Model Assessment for Insulin Resistance
  2. P1: Comparison of the mean of insulin resistance between the two groups of Ellagic acid and placebo (Independent samples t-test)
  3. P2: Comparison of mean of insulin resistance in each group at baseline and end of study (Paired samples t-test)